Proof
Technology · Antibody Mimetic Proteins™
A synthetic protein that behaves like an antibody, small enough to cross the tissue it needs to treat. Delivered to the eye, the lung and the skin instead of the bloodstream.
Read the scienceConventional antibodies are large, complex molecules. That size is why they work in the bloodstream, and why they stall everywhere else.
AMPs are engineered scaffolds that reproduce antibody-grade binding at roughly one fortieth of the size: small enough to move through tissue, rugged enough to survive the trip.
Because an AMP penetrates locally, it can be applied where the disease is. The dose stays in the tissue, so the systemic side-effect risk that shapes antibody therapy largely goes away.
Relative scale · schematic
A monoclonal antibody, drawn to scale.
What changes
Penetration, not circulation. An AMP is engineered under the size threshold that keeps antibodies out of the eye, the airway and the dermis.
Thermal stability replaces the 2–8 °C cold chain that governs how and where a monoclonal can be shipped and stored.
Cell-free synthesis removes bioreactor capacity from the critical path, so a new binder is a manufacturing change rather than a programme.
Local administration keeps the dose in the target tissue, which takes systemic exposure, and the risk profile built on it, off the table.
The shift
Team · portraits to be photographed
Four slots, shot on one consistent light setup against the brand navy, so the row reads as one piece rather than four different cameras.
